Skip to content
value.today

Dewpoint Therapeutics, Inc.

🇺🇸 Boston, Massachusetts, USABiotechnologyFounded 2018
Total raised
$304 M
3 rounds on record
Latest round
$77 M
Sep 2025
First round on record
Jul 2020
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Dewpoint Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2025$77 MNo. 3$50 to $250 million

Dewpoint Therapeutics, Inc.: Raise no. 3, Sep 2025

Investors in this round

23 investors had bought by the notice of Jul 13, 2026: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$77 M of $82 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ameet Nathwani, M.D. · Executive Officer, Director
  • Isaac A. Klein, M.D., Ph.D. · Executive Officer
  • Amir H. Nashat, Sc.D. · Director
  • Anthony A. Hyman, Ph.D. · Director
  • Giuseppe A. Ciaramella, Ph.D. · Director
  • Mark A. Murcko, Ph.D. · Director
  • Olivier Brandicourt, M.D. · Director
  • Regina Barzilay, Ph.D. · Director
  • Richard A. Young, Ph.D. · Director
  • Srinivas Akkaraju, M.D., Ph.D. · Director
  • Steven H. Neier, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ameet Nathwani, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 13, 2026. Read the notice at the SEC.

equitySEC
Jan 2022$150 MNo. 2$50 to $250 million

Dewpoint Therapeutics, Inc.: Raise no. 2, Jan 2022

Investors in this round

18 investors had bought by the notice of Feb 4, 2022: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$150 M of $150 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ameet A. Nathwani, M.D. · Director, Executive Officer
  • Isaac A. Klein, M.D., Ph.D. · Executive Officer
  • Joel D. Sendek · Executive Officer
  • Lori A. Escobedo · Executive Officer
  • Amir H. Nashat · Director
  • Anthony A. Hyman, Ph.D. · Director
  • Giuseppe H. Ciaramella, Ph.D. · Director
  • Juergen A. Eckhardt, M.D. · Director
  • Mark A. Murcko, Ph.D. · Director
  • Olivier H. Brandicourt, M.D. · Director
  • Regina A. Barzilay, Ph.D. · Director
  • Richard A. Young, Ph.D. · Director
  • Srinivas H. Akkaraju, M.D., Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ameet Nathwani, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 4, 2022. Read the notice at the SEC.

equitySEC
Jul 2020$77 MNo. 1$50 to $250 million

Dewpoint Therapeutics, Inc.: Raise no. 1, Jul 2020

Investors in this round

25 investors had bought by the notice of Nov 2, 2020: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$77 M of $77 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ameet A. Nathwani, M.D. · Director, Executive Officer
  • Amir H. Nashat · Executive Officer, Director
  • Bruce H. Beutel · Executive Officer
  • Anthony A. Hyman, Ph.D. · Director
  • Giuseeppe H. Ciaramella, Ph.D. · Director
  • Jurgen A. Eckhardt, M.D. · Director
  • Mark A. Murcko, Ph.D. · Director
  • Oliver H. Brandicourt, M.D. · Director
  • Richard A Young, Ph.D. · Director
  • Srinivas H. Akkaraju, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ameet Nathwani, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 2, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Dewpoint Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2026).

    SEC Form D · Jul 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2026

That is all the official record says: Dewpoint Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Dewpoint Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 25 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Dewpoint Therapeutics, Inc.
NameRoleNamed in
Ameet Nathwani, M.D.Executive officerJul 2026
Isaac A. Klein, M.D., Ph.D.Executive officerJul 2026
Elisabeth A. LeidermanExecutive officerSep 2025
Lori A. EscobedoExecutive officerSep 2025
Ameet A. Nathwani, M.D.Executive officerFeb 2022
Joel D. SendekExecutive officerFeb 2022
Amir H. NashatExecutive officerNov 2020
Bruce H. BeutelExecutive officerNov 2020
Ameet Nathwani, M.D.DirectorJul 2026
Amir H. Nashat, Sc.D.DirectorJul 2026
Anthony A. Hyman, Ph.D.DirectorJul 2026
Giuseppe A. Ciaramella, Ph.D.DirectorJul 2026
Mark A. Murcko, Ph.D.DirectorJul 2026
Olivier Brandicourt, M.D.DirectorJul 2026
Regina Barzilay, Ph.D.DirectorJul 2026
Richard A. Young, Ph.D.DirectorJul 2026
Srinivas Akkaraju, M.D., Ph.D.DirectorJul 2026
Steven H. Neier, Ph.D.DirectorJul 2026
Amir H. Nashat, Ph.D.DirectorSep 2025
Fabio H. Pucci, Ph.D.DirectorSep 2025
Guiseppe A. Ciaramella, Ph,D.DirectorSep 2025
Ameet A. Nathwani, M.D.DirectorFeb 2022
Amir H. NashatDirectorFeb 2022
Giuseppe H. Ciaramella, Ph.D.DirectorFeb 2022
Juergen A. Eckhardt, M.D.DirectorFeb 2022
Olivier H. Brandicourt, M.D.DirectorFeb 2022
Regina A. Barzilay, Ph.D.DirectorFeb 2022
Srinivas H. Akkaraju, M.D., Ph.D.DirectorFeb 2022
Giuseeppe H. Ciaramella, Ph.D.DirectorNov 2020
Jurgen A. Eckhardt, M.D.DirectorNov 2020
Oliver H. Brandicourt, M.D.DirectorNov 2020
Richard A Young, Ph.D.DirectorNov 2020
Srinivas H. Akkaraju, M.D.DirectorNov 2020